Skip to main content
TipRanks
Go Ultimate75% OFF

Cannapharmarx (CPMD) AI Stock Analysis

61 Followers
CPMD

Cannapharmarx

(Other OTC:CPMD)

Select Model
Rating:43Neutral
Price Target:$0.01â–²(400.00% Upside)
Action:reiterated
Date:11/20/26

The score is primarily driven by weak financial performance: declining TTM revenue, deeply negative profitability, and a stressed capital structure with negative equity and debt exceeding assets. Improved TTM operating and free cash flow provides some offset, but technical and valuation inputs are largely neutral/limited due to missing indicators and a negative P/E.

Positive Factors
Positive Operating Cash FlowThe return to positive operating cash flow indicates that the business generated cash from operations over the latest twelve months, improving near-term internal funding capacity. If sustained, this could reduce reliance on external financing, although the pack describes the improvement as fragile because losses remain substantial.
Negative Factors
Declining RevenueA roughly 30.5% TTM revenue decline signals weakening commercial momentum and reduces the scale available to absorb fixed operating costs. Continued contraction would make it harder to reach sustainable profitability, fund growth internally, and convert the recent cash-flow improvement into a durable trend.

Cannapharmarx (CPMD) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap
$1.42M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
0.08
Revenue Growth
-30.82%
EPS Growth
-26.13%
Country
US
Employees
26
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Cannapharmarx Business Overview & Revenue Model

Company Description

CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgary,...

How the Company Makes Money

null

Cannapharmarx Financial Statement Overview

Summary

Financials are weak overall: TTM revenue fell ~30.5% and profitability remains deeply negative (gross profit below zero with substantial operating and net losses). The balance sheet is highly stressed with persistent negative equity and debt (~$21.6M) far exceeding assets (~$7.3M). The main positive is improved TTM cash generation (operating cash flow ~$1.43M and free cash flow ~$1.48M), but it appears fragile given ongoing losses and limited implied debt-service capacity.

Income Statement

9Very Negative

Balance Sheet

6Very Negative

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.18M1.36M820.14K000
Gross Profit-1.35M-2.08M-2.94M-65.56K-295.00K-14.36K
EBITDA-7.36M-3.25M-7.53M-1.45M-4.91M-2.61M
Net Income-9.19M-11.13M-9.91M3.69M-8.53M-8.83M
Balance Sheet
Total Assets7.29M7.02M10.84M11.75M5.41M114.33K
Cash, Cash Equivalents and Short-Term Investments32.04K1,8042,1566502,31727.77K
Total Debt21.60M20.65M14.06M12.94M14.52M9.02M
Total Liabilities37.47M37.17M30.65M23.90M22.76M13.04M
Stockholders Equity-30.19M-30.15M-19.81M-12.15M-17.34M-12.93M
Cash Flow
Free Cash Flow1.48M-794.62K-1.70M-2.36M-1.56M-2.42M
Operating Cash Flow1.43M-789.10K-1.70M-2.27M-1.45M-2.41M
Investing Cash Flow-61.23K-5,5190-80.63K-116.00K493.62K
Financing Cash Flow-430.98K794.27K1.70M2.35M1.40M1.30M

Cannapharmarx Risk Analysis

Cannapharmarx disclosed 63 risk factors in its most recent earnings report. Cannapharmarx reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cannapharmarx Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CPMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
YCBDYCBD43Neutral$4.03M-1.17-34.25%―10.01%95.01%
CPMDCPMD43Neutral$1.42M-0.1430.29%―-30.82%-26.13%
XWELXWEL39Underperform$4.35M-0.08317.52%―-7.58%-30.33%
IMCCIMCC37Underperform$921.90K-0.02528.80%―-35.33%-110.11%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%300%XWELYCBDLEXXIMCCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CPMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CPMDCannapharmarx ―――
XWELXwell, Inc.0.41-0.32-43.84%
YCBDCbdmd INc0.36-0.16-30.77%
LEXXLexaria Bioscience Corp.4.03-11.87-74.65%
IMCCIm Cannabis Corp0.50-45.10-98.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026